AOD-9604 vs GLP-1 (Sema)
AOD-9604 and GLP-1 (Sema) both appear in metabolic and obesity research, but they target entirely different biological mechanisms. AOD-9604 is a fragment of human growth hormone (amino acids 176 to 191) studied for its ability to stimulate lipolysis in adipose tissue through mechanisms distinct from the full HGH molecule, without affecting insulin-like growth factor levels or triggering the diabetogenic effects associated with full HGH. GLP-1 (Sema) is a GLP-1 receptor agonist studied for glucose-dependent insulin secretion enhancement, appetite suppression via hypothalamic signaling, and gastric emptying delay. Researchers studying fat metabolism and metabolic disease frequently evaluate both to understand the different layers of metabolic intervention available.
AOD-9604
HGH fragment peptide (amino acids 176 to 191)
GLP-1 (Sema)
GLP-1 receptor agonist peptide
At a Glance
Key research profiles for each compound.
AOD-9604
HGH fragment studied for lipolysis and fat metabolism without growth effects
Class
HGH fragment peptide (amino acids 176 to 191)
Mechanism
Lipolysis activation, beta-3 adrenergic signaling, fat metabolism
Half-Life
Estimated short clearance in preclinical models
Research Area
Fat metabolism, adipose tissue, metabolic research
- Investigated for lipolysis stimulation in adipose tissue without IGF-1 elevation
- Studied for fat metabolism regulation via beta-3 adrenergic receptor interactions
- Examined for absence of diabetogenic or mitogenic effects seen with full HGH
- Documented as a fragment of HGH amino acids 176 to 191 in metabolic research
GLP-1 (Sema)
GLP-1 receptor agonist studied for insulin secretion and appetite regulation
Class
GLP-1 receptor agonist peptide
Mechanism
GLP-1R agonism, insulin secretion enhancement, appetite modulation
Half-Life
Extended via fatty acid conjugation in semaglutide analog design
Research Area
Metabolic disease, obesity, insulin sensitivity, appetite
- Investigated for GLP-1 receptor agonism and glucose-dependent insulin secretion
- Studied for appetite suppression via hypothalamic GLP-1 receptor signaling
- Examined for gastric emptying delay and satiety hormone modulation
- Documented glucoprotective effects in pancreatic beta cell models
Side-by-Side Comparison
Key research parameters compared directly.
| Feature | AOD-9604 | GLP-1 (Sema) |
|---|---|---|
| Compound Class | HGH fragment peptide (16 AA, residues 176 to 191) | GLP-1 receptor agonist peptide |
| Primary Mechanism | Lipolysis activation, beta-3 adrenergic signaling | GLP-1R agonism, insulin secretion, appetite suppression |
| Primary Research Target | Adipose tissue lipolysis and fat oxidation | Pancreatic beta cells, hypothalamus, GI tract |
| Insulin Effects | No documented effect on insulin levels in models | Glucose-dependent insulin secretion enhancement |
| IGF-1 Effects | No IGF-1 elevation, unlike full HGH | No direct IGF-1 axis involvement |
| Appetite Effects | Not a primary documented research mechanism | Documented appetite suppression via CNS GLP-1R signaling |
| Research Origin | Developed by Metabolic Pharmaceuticals, 1990s | Based on GLP-1 incretin hormone, extended via conjugation |
| Clinical Data | Phase 2a human trials; not approved | Multiple approved GLP-1 agonist drugs as comparators |
Research Deep-Dive
AOD-9604
AOD-9604 is a synthetic 16-amino acid peptide representing the C-terminal fragment (residues 176 to 191) of human growth hormone, with an additional tyrosine residue added at the N-terminus to improve stability. Unlike full HGH, AOD-9604 does not bind the growth hormone receptor in a way that stimulates IGF-1 production or promotes the diabetogenic effects associated with full HGH at supraphysiological doses. Preclinical studies in rodent and primate models have documented dose-dependent reductions in body fat, with proposed mechanisms involving stimulation of beta-3 adrenergic receptors in adipose tissue to promote lipolysis and fat oxidation. Human Phase 2a clinical trials for obesity were conducted in the early 2000s, with modest fat loss results reported.
View AOD-9604 →GLP-1 (Sema)
GLP-1 (Glucagon-like Peptide-1) receptor agonists like semaglutide are among the most clinically validated metabolic research compounds. The GLP-1 receptor is expressed on pancreatic beta cells, where agonism stimulates glucose-dependent insulin secretion without causing hypoglycemia in normoglycemic conditions. GLP-1 receptors in the hypothalamus and brainstem are responsible for the appetite-suppressing effects documented both in animal models and in human clinical trials. Gastric emptying delay contributes to post-meal satiety extension. In preclinical models, GLP-1 receptor agonism has also been studied for cardiovascular protection, neurological effects, and beta cell preservation in type 2 diabetes models.
View GLP-1 (Sema) →Research Context
AOD-9604 and GLP-1 (Sema) occupy different positions in the metabolic research landscape. AOD-9604 represents a targeted approach to adipose-specific lipolysis without systemic growth hormone effects. GLP-1 receptor agonism represents a broader metabolic intervention targeting insulin secretion, appetite, and gastric motility simultaneously. Researchers designing obesity or metabolic syndrome models may include both to study adipose-specific lipolysis (AOD-9604) alongside the broader incretin axis and appetite regulation (GLP-1).
Frequently Asked Questions
Related Comparisons
Source Both Compounds
AOD-9604 and GLP-1 (Sema) are both available from Spartan Peptides at ≥98% HPLC-verified purity. Domestic US supply, same-day dispatch before 2 PM. All products for in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.